Competitive Assay Patents (Class 435/7.93)
  • Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
    Patent number: 7579159
    Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: August 25, 2009
    Inventors: Paul Noel Holvoet, Désiré José Collen
  • NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE
    Publication number: 20090209474
    Abstract: The present invention relates to novel therapeutic uses of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof. Furthermore, the present invention relates to the use of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof, in obtaining methods of screening and of developing drugs. Finally, the present invention relates to the novel therapeutic use of other glutamine synthetase (GS) ligands and to the use of these ligands in obtaining methods for screening and developing drugs.
    Type: Application
    Filed: August 8, 2006
    Publication date: August 20, 2009
    Applicant: NEWTHERA
    Inventors: Jean-Christophe Roegel, Pierre Eftekhari
  • Modulation of nitric oxide signaling through signaling through specific regulation by arginylation and the N-end rule pathway
    Patent number: 7575881
    Abstract: Screening assays that allow for the identification of agents that modulate the activity of the arginylation branch of the N-end rule pathway are provided. Also provided are method of using an agent that modulate the activity of the arginylation branch of the N-end rule pathway to increase or decrease protein degradation in a cell, and to modulate physiologic and pathologic associated with N-end rule pathway mediated arginylation.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: August 18, 2009
    Assignee: California Institute of Technology
    Inventors: Rong-Gui Hu, Jun Sheng, Yong Tae Kwon, Anna Kashina, Alexander Varshavsky
  • Caffeine detection using internally referenced competitive assays
    Patent number: 7569396
    Abstract: Methods, compositions, and apparatus for detecting the presence of caffeine in a liquid sample are provided. In certain embodiments, an internally referenced competitive assay allows a very precise determination of a threshold value of caffeine for use in semiquantitative types of ligand-receptor assays. By using a detection means that participates in two assays, sensitivity is doubled in the maximum sensitivity range and the range can be adjusted to match the predicted concentration range of an analyte. This format and the materials described herein allow the assay to complete within three minutes. In addition, this format accommodates common attributes of liquid samples for detecting caffeine, such as the inclusion of milk or sugar in a coffee-type beverage.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: August 4, 2009
    Assignee: PurpleCow LLC
    Inventors: Anaflor Q. Graham, Carralee Hathaway, Mark S. Geisberg
  • Doxorubicin immunoassay
    Patent number: 7569358
    Abstract: Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: August 4, 2009
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
  • Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors
    Publication number: 20090192170
    Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof (I), wherein: R3 is cyclopentyl or cyclohexyl; X is CH or N; and R4 is optionally substituted C1-8 alkyl or optionally substituted C3-8 cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as bone metastases and associated pain.
    Type: Application
    Filed: January 8, 2009
    Publication date: July 30, 2009
    Inventors: Martin Quibell, John Paul Watts
  • Modulators of angiogenesis and tumorigenesis
    Patent number: 7566546
    Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: July 28, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Sacha J. Holland, Weiduan Xu
  • Immunoassay for LSD and 2-oxo-3-hydroxy-LSD
    Patent number: 7566549
    Abstract: The present invention provides hapten derivatives useful for the preparation of antigens, antibodies and reagents for use in immunoassays for the detection of LSD and 2-oxo-3-hydroxy LSD. In the present invention, the 2-oxy LSD nucleus is derivatized out of the indole nitrogen to form an aminoalkyl derivative. The resulting haptens can then be further modified at this functionalized position for linking to appropriate immunogenic or labeling groups to provide reagents for immunoassays having substantially equal specificity for both LSD and 2-oxo-3-hydroxy-LSD.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: July 28, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Mitali Ghoshal, Gerald F. Sigler, Alan J. McNally
  • Use of protein ASC as a marker for breast cancer
    Patent number: 7566542
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein ASC in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: July 28, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
  • Flexible Carbohydrate-Bearing Polymer
    Publication number: 20090187084
    Abstract: A sensor for the detection or measurement of a carbohydrate analyte in fluid comprises components of a competitive binding assay the readout of which is a detectable or measurable optical signal retained by a material that permits diffusion of the analyte but not the assay components, the assay components comprising: a carbohydrate binding molecule labelled with one of a proximity based signal generating/modulating moiety pair; and a carbohydrate analogue capable of competing with the analyte for binding to the carbohydrate binding molecule, the carbohydrate analogue being a flexible water-soluble polymer comprising: polymerized or co-polymerised residues of monomer units, the monomer unit residues bearing pendant carbohydrate or carbohydrate mimetic moieties and pendant moieties which are the other of the proximity based signal generating/modulating moiety pair.
    Type: Application
    Filed: December 6, 2006
    Publication date: July 23, 2009
    Applicant: PRECISENCE A/S
    Inventors: Jesper Svenning Kristensen, Klaus Gregorius, Casper Struve, Yihua Yu
  • Homogeneous enzyme immunoassay for simultaneous detection of multiple analytes
    Patent number: 7560239
    Abstract: Methods and kits are provided for the simultaneous detection of multiple analytes, i.e. to the determination of whether one or more of a plurality of analytes is present in a sample, particularly the plurality of analytes are structurally unrelated or significantly different, particularly to whether one or more of such analytes is present in a sample in a concentration that is above a predetermined minimum or cutoff value, and particularly for such analytes with different cutoffs. The methods and kits are particularly useful for-screening for the presence of a plurality of drugs (licit and/or illicit), performance-enhancing substances, and other chemicals, and involve a competitive enzyme immunoassay employing one or more conjugates of G6PDH with a plurality of the analytes.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: July 14, 2009
    Assignee: Lin-Zhi International Inc.
    Inventors: Marie Lin, Tom Chia, Chiu Chin Chang
  • Method of evaluating a subject for risk or predisposition of reduced renal function over time
    Patent number: 7560244
    Abstract: The invention includes diagnostic, predictive, prognostic and monitoring methods and reagents for loss of renal function, e.g., diabetic nephropathy and end stage renal disease (ESRD).
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: July 14, 2009
    Assignee: Joslin Diabetes Center, Inc.
    Inventors: Andrzej S. Krolewski, James H. Warram
  • RBP4 in insulin sensitivity/resistance, diabetes, and obesity
    Patent number: 7553631
    Abstract: Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: June 30, 2009
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Barbara B. Kahn, Qin Yang, Tim Graham, Odile Peroni
  • Methods to Identify Protein Arginine Deiminase 4 Inhibitors
    Publication number: 20090162877
    Abstract: In accordance with one embodiment of the present disclosure, a method to identify a protein arginine deiminase 4 inhibitor is disclosed. The method includes performing a competitive assay in which a potential inhibitor compound competes with rhodamine-conjugated fluoroamidine to bind to protein arginine deiminase 4. Fluorescence is measured to determine an estimate of the amount of fluorescent protein arginine deiminase 4 that is present in the assay.
    Type: Application
    Filed: October 31, 2008
    Publication date: June 25, 2009
    Applicant: University of South Carolina
    Inventors: Paul Ryan Thompson, Bryan Knuckley
  • Biologically active compounds
    Publication number: 20090131502
    Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilate degradation.
    Type: Application
    Filed: February 25, 2008
    Publication date: May 21, 2009
    Inventors: Martin Quibell, John Paul Watts, Yikang Wang, Lee Patient, Jonathan R. Heal
  • DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1 AUTOANTIBODIES
    Publication number: 20090123415
    Abstract: Methods of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1? autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1? autoantibodies.
    Type: Application
    Filed: July 26, 2006
    Publication date: May 14, 2009
    Applicant: Xbiotech, Inc.
    Inventors: John Simard, Klaus Bendtzen
  • Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
    Patent number: 7524642
    Abstract: Provided are methods and compositions for assaying for ubiquitin agents that are enzymatic components of ubiquitin-mediated proteolysis and, more particularly, methods and compositions for assaying for agents that modulate the activity of such ubiquitin agents.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: April 28, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
  • Humanized Fc?RIIB-specific antibodies and methods of use thereof
    Patent number: 7521542
    Abstract: The present invention relates to humanized Fc?RIIB antibodies, fragments, and variants thereof that bind human Fc?RIIB with a greater affinity than said antibody binds Fc?RIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express Fc?RIIB.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: April 21, 2009
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Rabbit monoclonal antibody against Id1 protein
    Patent number: 7517663
    Abstract: The present invention relates to a rabbit monoclonal antibody that binds to human Id1 protein and/or mouse Id1 protein with high specificity and high affinity. The antibody has a binding constant, measured with respect to human Id1 protein and/or mouse Id1 protein, equal to or greater than 1×108/molar. The antibody has no substantial cross-reactivity with other family Id proteins such as Id2, Id3, or Id4, or other endogenous proteins present in the cells that express Id1 protein. The high specificity and high affinity of the rabbit monoclonal antibodies of the present invention allows sensitive and specific detection and/or quantitation of Id1 protein in biological samples. The antibodies are useful in immunochemical-based assays such as ELISA, western blot, and immunohistochemical staining.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: April 14, 2009
    Assignees: Biocheck, Inc., Angiogenex, Inc.
    Inventors: Jung-Shou Chen, William A. Garland
  • Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
    Patent number: 7517517
    Abstract: The present invention is concerned with radiolabelled quinoline and quinolinone derivatives according Formula (I-A)* or (I-B)* showing metabotropic glutamate receptor antagonistic activity, in particular mGlu1 receptor activity, and their preparation; it further relates to compositions comprising them, as well as their use for marking and identifying metabotropic glutamate receptor sites and for imaging an organ.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: April 14, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Anne Simone Josephine Lesage, François Paul Bischoff, Cornelus Gerardus Maria Janssen, Hilde Lavreysen
  • Diagnostic assay and method of treatment involving macrophage inhibitory cytokine-1 (MIC-1)
    Patent number: 7514221
    Abstract: Methods for diagnosing risk of miscarriage and/or premature birth. The method comprises (i) determining the amount of (MIC-1) present in a body sample taken from a pregnant test subject having a known gestation age and (ii) comparing the determined amount against the amount, or range of amounts, present in equivalent body sample(s) taken from normal pregnant subject(s) of a gestation age which is substantially equivalent to the known gestation age of the test subject.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: April 7, 2009
    Assignee: St. Vincent's Hospital Sydney Limited
    Inventors: Samuel Norbert Breit, David Alexand Brown
  • Assays
    Publication number: 20090081714
    Abstract: Methods and assays for monitoring the cardiac health of a subject are provided. The method involves the detection of a urotensin surrogate in a sample leading to a more accurate and reliable diagnosis of early or late stages of decompensated heart failure, heart failure, risk of a heart failur in a subject than the measurement of the cyclic peptide of urotensin alone.
    Type: Application
    Filed: July 10, 2006
    Publication date: March 26, 2009
    Applicant: Inverness Medical Switzerland GMBH
    Inventors: Leong Ng, Sarah Johnson, Steve Eida, Paul Sheard
  • Rapid immunoassay of anthrax protective antigen in vaccine cultures and bodily fluids by fluorescence polarization
    Patent number: 7504202
    Abstract: The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a Bacillus anthracis protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of Fluorescence Polarization, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0.1 to 10.0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including B. anthracis by fluorescent methods.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: March 17, 2009
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Malford E. Cullum, Paul Hine, Lloyd G. Simonson, Chun N. Shih, Diane R. Bienek, Sukjoon Park, James C. Ragain, Jr., Linda A. Lininger
  • MARKER FOR PROLONGED RUPTURE OF MEMBRANES
    Publication number: 20090068692
    Abstract: The present invention relates to amniotic fluid specific polypeptide and a method for detecting rupture of the amniotic membranes. In particular the invention provides a marker for prolonged rupture of the membranes (PROM), which marker consists essentially of polypeptides of approximately 75 kDa, 20 kDa and 50 kDa as determined by 4-15% gradient SDS-PAGE under reducing conditions.
    Type: Application
    Filed: September 15, 2006
    Publication date: March 12, 2009
    Inventor: Victor Voroteliak
  • Compositions and methods comprising binding proteins for adalimumab
    Publication number: 20090068172
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Application
    Filed: August 27, 2008
    Publication date: March 12, 2009
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Identification of antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
    Patent number: 7498143
    Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: March 3, 2009
    Assignee: University of Florida Research Foundation
    Inventors: Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
  • ANTI-ANTIBODY REAGENT
    Publication number: 20090053743
    Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 26, 2009
    Inventors: William F. Link, Renato B. Del Rosario, Randy Sweet, David L. King
  • Electrochemiluminescence of rare earth metal chelates
    Patent number: 7494820
    Abstract: Luminescent chemical reagents that include complexes of rare earth metals with ligands such as aromatic heterocyclic nitrogen-containing compounds and semi-aromatic oxygen-containing compounds are used to detect small quantities of complex substances such as pharmaceuticals, metabolites, and microorganisms in complex sample mixtures.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: February 24, 2009
    Assignee: Bioveris Corporation
    Inventors: Hongjun Yang, Nicholas Cairns
  • Homogeneous immunoassays for multiple allergens
    Patent number: 7491553
    Abstract: A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: February 17, 2009
    Assignee: ImmuneTech, Inc.
    Inventors: Christopher R. Brown, James T. Murai
  • Disease markers for early stage atherosclerosis
    Patent number: 7482174
    Abstract: The invention relates to methods of diagnosing early stages of atherosclerosis.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: January 27, 2009
    Assignee: University of Massachusetts
    Inventors: Charles R. Kiefer, L. Michael Snyder, James B. McKenney, Jane F. Trainor
  • High-risk human papillomavirus detection
    Patent number: 7482142
    Abstract: This invention provides compositions and methods for detecting HPV in a sample. This invention also provides related kits, systems, and computers.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: January 27, 2009
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Janet Kornegay, Carrie L. Aldrich, Stephen G. Will
  • Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2)
    Patent number: 7465549
    Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: December 16, 2008
    Assignee: UCB, S.A.
    Inventors: Berkley Lynch, Karl Nocka, Bruno Fuks
  • Apparatus, system, and method of detecting an analyte utilizing pyroelectric technology
    Patent number: 7465427
    Abstract: A system for the measurement of a target analyte is provided including a detection apparatus and a reading apparatus. The detection apparatus, or “carrier”, includes a pyroelectric transducer (“pyroelectric film”) and one or more reagent concentrations (“reagent deposit”) deposited on the film. The reagent deposits are adapted to react with, and thus, detect the presence of a target analyte present in the local environment. Upon detection of the target analyte by the reagent deposit, the reading apparatus and the pyroelectric film may be used to detect the amount of heat that can be absorbed by the reagent deposit in response to irradiation. The pyroelectric film then delivers to the reader a signal corresponding to heat detected and the reader provides a corresponding indication of the concentration of the target substance detected.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: December 16, 2008
    Inventors: Bryan Truex, Charles Loomis
  • Identification of activated receptors and ion channels
    Patent number: 7462457
    Abstract: The present invention related to methods and reagents for generating and using activating mutations of receptors and ion channels.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: December 9, 2008
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Philip A. Beachy, Jussi Taipale
  • Docetaxel immunoassay
    Patent number: 7459281
    Abstract: Novel conjugates of docetaxel and novel docetaxel immunogens derived from the 7 and 10 positions of docetaxel and monoclonal antibodies generated by these docetaxel linked immunogens are useful in immunoassays for the quantification and monitoring of docetaxel in biological fluids.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: December 2, 2008
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Gregory Drake Lundell, Mahmoud Ahmed ElSohly, Waseem Gul
  • Detection of bovine viral diarrhea virus in hair samples
    Patent number: 7459269
    Abstract: The present invention relates to a method of detecting whether a target animal is Bovine Viral Diarrhea Virus (BVDV) positive or negative by determining whether a gp48 protein-specific reagent binds to a gp48 Bovine Viral Diarrhea Virus protein or protein fragment, which retains antigenic specificity, from a target animal's hair sample.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: December 2, 2008
    Assignees: Cornell Research Foundation, Inc., IDEXX Laboratories, Inc.
    Inventors: Roy Huchzermeier, Edward Joseph Dubovi
  • BLOOD SAMPLE HANDLING METHODS FOR IMPROVED ASSAYS FOR MYELOPEROXIDASE
    Publication number: 20080286818
    Abstract: The invention provides a method for determining concentration of myeloperoxidase (MPO) in a human blood sample comprising: (a) providing a human peripheral blood sample stored under MPO preservation conditions; and (b) determining concentration of MPO in a plasma sample derived from the human peripheral blood sample. In a preferred embodiment, the MPO preservation conditions used in the invention comprise storage of the human peripheral blood sample in a plasma collection tube containing a leukocyte MPO secretion inhibitor. In this embodiment, the leukocyte MPO secretion inhibitor is preferably ethylene diamine tetraacetic acid (EDTA). The assays used in the inventive methods can comprise any clinically useful assay for determining MPO plasma concentration, including sandwich and competitive immunoassays, clinical chemistry assays and enzymatic assays.
    Type: Application
    Filed: May 18, 2007
    Publication date: November 20, 2008
    Inventors: Saul A. Datwyler, Stephen C. Hsu, Matthew S. Matias, David P. Pacenti, Jessie W. Shih
  • Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
    Publication number: 20080286819
    Abstract: The present invention provides reagents, methods and systems for predicting the cytotoxic activity of an antibody or variant thereof comprising: determining a binding affinity of the antibody or variant thereof to a Fc activating receptor; determining a binding affinity of the antibody or variant thereof to a Fc inhibitory receptor, and calculating the ratio of said activating binding affinity to said inhibitory binding affinity (A/I ratio), wherein the magnitude of said ratio is an indication of the cytotoxic activity of the antibody or variant thereof. The present invention also provides purified modified antibodies having altered A/I ratios as compared to the unmodified antibodies.
    Type: Application
    Filed: October 27, 2006
    Publication date: November 20, 2008
    Inventors: Jeffrey V. Ravetch, Falk Nimmerjahn
  • Assay
    Patent number: 7452731
    Abstract: A method for determining the risk of an individual of suffering from inflammation, opportunistic infection or disruption of immunoglobulin metabolism, comprising (a) determining the level of fragmentation or modification of Fc function of immunoglobulins in a sample taken from the individual and (b) determining thereby the risk of inflammation, impaired immune response or opportunistic infection. The invention also provides the use of a trypsin inhibitor in the manufacture of a medicament for use in the treatment or prevention of a disorder associated with elevated trypsin activity which is correlated with IgG fragmentation or modification.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: November 18, 2008
    Inventor: Ivan Mikhailovich Petyaev
  • Detection of bovine viral diarrhea virus in tissue samples
    Patent number: 7449288
    Abstract: The present invention relates to a method of detecting whether a target animal is Bovine Viral Diarrhea Virus (BVDV) positive or negative by determining whether a gp48 protein-specific reagent binds to a gp48 Bovine Viral Diarrhea Virus protein or protein fragment, which retains antigenic specificity, from a target animal's tissue sample.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: November 11, 2008
    Assignees: Cornell Research Foundation, Inc., IDEXX Laboratories, Inc.
    Inventors: Roy Huchzermeier, Edward Joseph Dubovi
  • Mutants of the factor VII-activating protease and detection methods using specific antibodies
    Patent number: 7442514
    Abstract: Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: October 28, 2008
    Assignee: CSL Behring GmbH
    Inventors: Juergen Roemisch, Hans-Arnold Stoehr, Annette Feussner, Wiegand Lang, Thomas Weimer, Margret Becker, Claudia Nerlich, Gudrun Muth-Naumann, Bernd Knoblauch
  • Antibody specific to central nervous system tau protein
    Patent number: 7442516
    Abstract: The present invention provides an antibody which specifically recognizes a CNS tau protein but not a peripheral tau protein. More specifically, the present invention provides an antibody obtainable by using a polypeptide comprising an amino acid sequence of a connective portion between the amino acid sequence encoded by Exon 4 of a gene encoding a tau protein and the amino acid sequence encoded by Exon 5 thereof as an epitope specific to the isoform of tau protein predominantly existing in central nervous tissues. The present invention further provides a method of detecting Alzheimer's disease and a reagent kit using the antibody.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: October 28, 2008
    Assignees: Mitsubishi Chemical Corporation, Mitsubishi Kagaku Iatron, Inc.
    Inventors: Hideto Ohno, Koichi Ishiguro, Masaki Imagawa
  • Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
    Publication number: 20080254031
    Abstract: Genes and variant RNAs that are differentially expressed in human colon tumor tissues compared with normal colon tissue and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of colon cancer.
    Type: Application
    Filed: September 7, 2005
    Publication date: October 16, 2008
    Applicant: EXONHIT THERAPEUTICS SA
    Inventors: Kevin McGowan, Vinayaka Kotraiah, Michael Brenner, Richard Einstein, Laurent Bracco
  • Methods for the determination of antibody IgG avidity
    Patent number: 7432046
    Abstract: The present invention relates to methods of determining anti-infectious agent IgG avidity, for example, human anti-cytomegalovirus and human anti-toxoplasma IgG avidity, using a competitive assay format.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: October 7, 2008
    Assignee: Abbott Laboratories
    Inventors: Gregory T. Maine, Stephen C. Hsu, Darwin D. Smith, Dominick L. Pucci, Jörg Herzogenrath, Ingo Curdt, Heike Maria Christ
  • EIA for monitoring legionella pneumophila presence in water samples
    Publication number: 20080241864
    Abstract: A qualitative and quantitative EIA for detecting L. pneumophila in water samples is disclosed. Critical to the disclosed levels of sensitivity of these EIA's is the use of antigen-specific antibodies to the target L. pneumophila antigen that have been rendered antigen-specific by affinity purification on a chromatographic column, which antibodies and their purification are described in detail in parent application Serial No. 09/139,720 filed Aug. 25, 1998.
    Type: Application
    Filed: October 31, 2007
    Publication date: October 2, 2008
    Applicant: Binax, Inc.
    Inventors: Norman J. Moore, Myron Whipkey, James W. Welch
  • Methods of using bioelastomers
    Patent number: 7429458
    Abstract: Bioelastomers are disclosed for use in methods of binding compounds including immunoassay methods, in biosensors and methods or regenerating biosensors, and in methods for targeting the delivery of a compound to a particular location within an animal subjects. In general, the bioelastomer is conjugated to a binding compound, which is in turn used to bind a compound of interest. For targeted compound delivery, the bioelastomer is conjugated to the compound to be delivered.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: September 30, 2008
    Assignee: Duke University
    Inventor: Ashutosh Chilkoti
  • Apparatus, system, and method of detecting an analyte utilizing pyroelectric technology
    Patent number: 7429357
    Abstract: A system for the measurement of a target analyte is provided including a detection apparatus and a reading apparatus. The detection apparatus, or “carrier”, includes a pyroelectric transducer (“pyroelectric film”) and one or more reagent concentrations (“reagent deposit”) deposited on the film. The reagent deposits are adapted to react with, and thus, detect the presence of a target analyte present in the local environment. Upon detection of the target analyte by the reagent deposit, the reading apparatus and the pyroelectric film may be used to detect the amount of heat that can be absorbed by the reagent deposit in response to irradiation. The pyroelectric film then delivers to the reader a signal corresponding to heat detected and the reader provides a corresponding indication of the concentration of the target substance detected.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: September 30, 2008
    Inventors: Bryan Truex, Charles Loomis
  • Apparatus, system, and method of detecting an analyte utilizing pyroelectric technology
    Patent number: 7425310
    Abstract: A system for the measurement of a target analyte is provided including a detection apparatus and a reading apparatus. The detection apparatus, or “carrier”, includes a pyroelectric transducer (“pyroelectric film”) and one or more reagent concentrations (“reagent deposit”) deposited on the film. The reagent deposits are adapted to react with, and thus, detect the presence of a target analyte present in the local environment. Upon detection of the target analyte by the reagent deposit, the reading apparatus and the pyroelectric film may be used to detect the amount of heat that can be absorbed by the reagent deposit in response to irradiation. The pyroelectric film then delivers to the reader a signal corresponding to heat detected and the reader provides a corresponding indication of the concentration of the target substance detected.
    Type: Grant
    Filed: January 29, 2005
    Date of Patent: September 16, 2008
    Inventors: Bryan Truex, Charles Loomis
  • Busulfan immunoassay
    Patent number: 7423131
    Abstract: Novel conjugates of busulfan and novel busulfan immunogens derived from ?-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: September 9, 2008
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
  • Rapamycin assay
    Patent number: RE40596
    Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: December 2, 2008
    Assignee: Novartis AG
    Inventors: Richard Sedrani, Valerie Quesniaux Ryffel